Danaher (NYSE: DHR) reported Q2 EPS of $1.44, $0.36 better than the analyst estimate of $1.08. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $4.94 billion.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "We are very pleased with our second quarter results—especially in such a challenging environment. Our solid revenue growth, strong cash flow generation and more than 30% adjusted EPS growth are a testament to our team's commitment to the Danaher Business System and the outstanding portfolio of businesses that comprise Danaher today."

Joyce continued, "We are tackling the challenges presented by the COVID-19 pandemic head-on, providing critical diagnostic testing capabilities and accelerating our customers' pursuit of new vaccines and treatments. We're fortunate to navigate through this environment from a position of strength and believe that the combination of our team's DBS-driven execution, resilient portfolio and strong balance sheet uniquely position Danaher in 2020 and beyond."

For earnings history and earnings-related data on Danaher (DHR) click here.